Therefore, these results indicate that MCPIP-1 could alleviate the activities of neutrophils in IBD and that MG-132 as an inducer of MCPIP-1 overexpression may serve as a potential therapeutic approach in the management of IBD. This evidence concerns the gene ZC3H12A and inflammatory bowel disease.